Esperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of ($0.11), $0.03 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $69.11 million versus the consensus estimate of $63.45 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.